Individualized Therapies For Non-Hodgkin’s Lymphoma

Positron emission tomography (PET) could be an important tool for identifying non-Hodgkin’s lymphoma patients who are likely to respond well to treatment with 90 ibritumomab tiuxetan (IT) - the first radioimmunotherapy treatment approved for use by the U.S. Food and Drug Administration, said researchers at SNM’s 55th Annual Meeting.

More: continued here

Filed under: Lymphoma / Leukemia on June 19th, 2008